REFERENCES
1. Lassaletta A, Guerreiro Stucklin A, Ramaswamy V, et al. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer . Nov 2016;63(11):2038-41. doi:10.1002/pbc.26086
2. Chiu B, Chan J, Das S, Alshamma Z, Sergi C. Pediatric Sarcoidosis: A Review with Emphasis on Early Onset and High-Risk Sarcoidosis and Diagnostic Challenges. Diagnostics (Basel) . Oct 25 2019;9(4)doi:10.3390/diagnostics9040160
3. Huh JY, Moon DS, Song JW. Sarcoid-like reaction in patients with malignant tumors: Long-term clinical course and outcomes. Front Med (Lausanne) . 2022;9:884386. doi:10.3389/fmed.2022.884386
4. Beijer E, Roodenburg-Benschop C, Schimmelpennink MC, Grutters JC, Meek B, Veltkamp M. Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype.Cells . Mar 7 2021;10(3)doi:10.3390/cells10030585
5. Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition.Oncoimmunology . 2018;7(9):e1468955. doi:10.1080/2162402X.2018.1468955
6. Baumann D, Hagele T, Mochayedi J, et al. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nat Commun . May 1 2020;11(1):2176. doi:10.1038/s41467-020-15979-2
7. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med . Apr 15 2020;201(8):e26-e51. doi:10.1164/rccm.202002-0251ST
8. Anastasopoulou A, Diamantopoulos PT, Skalioti C, et al. The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. Ther Adv Med Oncol . 2021;13:17588359211047349. doi:10.1177/17588359211047349
9. Bala VM, Mitsogianni M, Laschos K, et al. Mediastinal and hilar sarcoid-like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature. Mol Clin Oncol . May 2022;16(5):99. doi:10.3892/mco.2022.2532
10. Dando EE, Rosenbach M, English III JC. Granulomatous drug reactions from targeted therapeutics. Medical Research Archives . 2020-06-18 2020;8(6)doi:10.18103/mra.v8i6.2138
11. Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol . Mar 2014;150(3):307-11. doi:10.1001/jamadermatol.2013.7919
12. van Moorsel CH, Christiani DC. Genetic susceptibility to sarcoidosis, a chronic inflammatory disorder. Am J Respir Crit Care Med . Nov 1 2012;186(9):816-8. doi:10.1164/rccm.201209-1582ED
13. Calender A, Weichhart T, Valeyre D, Pacheco Y. Current Insights in Genetics of Sarcoidosis: Functional and Clinical Impacts. J Clin Med . Aug 13 2020;9(8)doi:10.3390/jcm9082633
14. Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol . 2013;2013:513782. doi:10.1155/2013/513782
15. Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn’s disease.RMD Open . 2015;1(1):e000097. doi:10.1136/rmdopen-2015-000097
16. Tsao YP, Tseng FY, Chao CW, et al. NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression. The Journal of clinical investigation . Feb 1 2023;133(3)doi:10.1172/jci157272
17. Nobre L, Zapotocky M, Ramaswamy V, et al. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precis Oncol . 2020;4doi:10.1200/PO.19.00298